0001179110-22-003077.txt : 20220518 0001179110-22-003077.hdr.sgml : 20220518 20220518171228 ACCESSION NUMBER: 0001179110-22-003077 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220516 FILED AS OF DATE: 20220518 DATE AS OF CHANGE: 20220518 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SEVERINO MICHAEL CENTRAL INDEX KEY: 0001609447 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22940141 MAIL ADDRESS: STREET 1: 1 N. WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 edgar.xml FORM 4 - X0306 4 2022-05-16 0 0001551152 AbbVie Inc. ABBV 0001609447 SEVERINO MICHAEL 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 0 1 0 0 Vice Chairman Common Stock, $0.01 par value 2022-05-16 4 M 0 70879 61.36 A 222982 D Common Stock, $0.01 par value 2022-05-16 4 M 0 29121 79.02 A 252103 D Common Stock, $0.01 par value 2022-05-16 4 S 0 46273 154.04 D 205830 D Common Stock, $0.01 par value 2022-05-16 4 S 0 53327 154.80 D 152503 D Common Stock, $0.01 par value 2022-05-16 4 S 0 400 155.44 D 152103 D Common Stock, $0.01 par value 2022-05-17 4 M 0 35364 79.02 A 187467 D Common Stock, $0.01 par value 2022-05-17 4 M 0 64636 93.50 A 252103 D Common Stock, $0.01 par value 2022-05-17 4 S 0 43621 153.43 D 208482 D Common Stock, $0.01 par value 2022-05-17 4 S 0 54279 154.49 D 154203 D Common Stock, $0.01 par value 2022-05-17 4 S 0 2100 155.27 D 152103 D Option (Right to Buy) 61.36 2022-05-16 4 M 0 70879 61.36 D 2018-02-16 2027-02-15 Common Stock 70879 0 D Option (Right to Buy) 79.02 2022-05-16 4 M 0 29121 79.2 D 2020-02-21 2029-02-20 Common Stock 29121 35364 D Option (Right to Buy) 79.02 2022-05-17 4 M 0 35364 79.02 D 2020-02-21 2029-02-20 Common Stock 35364 0 D Option (Right to Buy) 93.50 2022-05-17 4 M 0 64636 93.50 D 2021-02-20 2030-02-19 Common Stock 64636 49930 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.38 to $154.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.38 to $154.81 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.44. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.95 to $153.92 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.02 to $155.00 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.27. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Steven L. Scrogham, attorney-in-fact for Michael Severino 2022-05-18